- Home
- KPTI vs WWR Comparison
KPTI vs WWR Comparison
Compare KPTI & WWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- WWR
- Stock Information
- Founded
- KPTI 2008
- WWR 1977
- Country
- KPTI United States
- WWR United States
- Employees
- KPTI N/A
- WWR N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- WWR Metal Mining
- Sector
- KPTI Health Care
- WWR Basic Materials
- Exchange
- KPTI Nasdaq
- WWR Nasdaq
- Market Cap
- KPTI 44.5M
- WWR 48.0M
- IPO Year
- KPTI 2013
- WWR N/A
- Fundamental
- Price
- KPTI $5.92
- WWR $0.79
- Analyst Decision
- KPTI Buy
- WWR Strong Buy
- Analyst Count
- KPTI 6
- WWR 2
- Target Price
- KPTI $39.80
- WWR $2.00
- AVG Volume (30 Days)
- KPTI 221.8K
- WWR 2.1M
- Earning Date
- KPTI 08-11-2025
- WWR 08-07-2025
- Dividend Yield
- KPTI N/A
- WWR N/A
- EPS Growth
- KPTI N/A
- WWR N/A
- EPS
- KPTI N/A
- WWR N/A
- Revenue
- KPTI $137,269,000.00
- WWR N/A
- Revenue This Year
- KPTI $2.18
- WWR N/A
- Revenue Next Year
- KPTI $11.28
- WWR N/A
- P/E Ratio
- KPTI N/A
- WWR N/A
- Revenue Growth
- KPTI N/A
- WWR N/A
- 52 Week Low
- KPTI $3.51
- WWR $0.45
- 52 Week High
- KPTI $16.95
- WWR $1.32
- Technical
- Relative Strength Index (RSI)
- KPTI 72.07
- WWR 57.08
- Support Level
- KPTI $3.65
- WWR $0.65
- Resistance Level
- KPTI $4.35
- WWR $0.79
- Average True Range (ATR)
- KPTI 0.50
- WWR 0.06
- MACD
- KPTI 0.17
- WWR -0.01
- Stochastic Oscillator
- KPTI 70.06
- WWR 72.53
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About WWR Westwater Resources Inc.
Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.